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ABSTRACT 
 
This study was conducted to measure cell-mediated immune response in healthy 
Epstein Barr virus (EBV)–seropositive individuals using a tissue culture "growth 
inhibition" assay (regression assay) where peripheral blood lymphocytes (PBLs) were 
tested for their ability to inhibit the outgrowth of the autologous lymphoblastoid cell 
lines (LCLs). Inhibition of the outgrowth of the autologous LCLs was seen after 4 
weeks by the addition of PBLs from healthy EBV seropositive donors. The regression 
phenomenon was never seen when the donors of peripheral blood lymphocytes were 
EBV- seronegative. Regression assay showed that EBV- specific memory T cells were 
stable in healthy EBV seropositive over many years, which indicates the persistent 
nature of EBV infection. 
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INTRODUCTION 
 
The Epstein-Barr virus (EBV) is a human viral 
pathogen with a 170kb double stranded DNA genome 
and has demonstrable oncogenic potential.1 In the 
course of primary human infection with EBV the 
agent infects epithelial cells of the oropharynx2,3 and 
circulating lymphocytes which have differentiated 
toward immunoglobulin production.4 Epithelial cell 
infection persists for years. Although lymphocyte 
infection also persists for life, there is little or no virus 
replication in lymphocytes. Infection is therefore said 
to be latent in these cells.4 Lymphocyte infection 
results in cell proliferation.4 In normal people, 
however, the latently infected lymphocytes are 
suppressed or killed by immune T and NK 
lymphocytes.5 Since latently infected lymphocytes 
can be specifically killed by immune T cells they 
must be expressing a new cell surface antigen. When 
EBV infects B lymphocytes the cell becomes 
immortalized to perpetual growth6 to produce EB 
virus transformed lymphoblastoid cell lines (LCLs). 
 
Corresponding Author: Mahmood Mahmoodian Shooshtari, PhD; 
Iranian Blood Transfusion Organisation, Research centre, Tehran, 
Iran. Tel: (+98 21) 8828 8583, Fax: (+98 21) 8827 0001,  
E-mail: shooshtari@ibto.ir  
LCLs express a limited set of EBV proteins known as 
the latency-associated proteins.7  
EBV is widespread in the human population and more 
than 95% of adults are EBV seropositive and possess 
memory T-cells in their peripheral blood.4 A key 
factor in maintaining a virus-host balance appears to 
be the cell-mediated immune response.8,9 T cell 
response can be evaluated using a tissue culture 
growth inhibition assay (regression assay) or by a 
chromium-51 release assay.10-12 Compared to 
radioactive isotope techniques such as a 51Cr release 
assay, the growth inhibition assay is safer and 
economical (no radioactive isotopes are used, no 
additional reagents like scintillation fluid is required). 
Also the results obtained strongly correlate to those 
obtained with other techniques. The regression assay 
is so called because in vitro, EBV infected 
lymphocytes transform in the 14 days post infection 
and subsequently these infected B cells die or regress 
due to the activation of a specific T-cell response in 
the same culture.10,12 In this study, cell mediated 
immune response to EBV in man was measured in 
vitro using a tissue culture "regression assay" where 
peripheral blood lymphocytes were tested for their 
ability to inhibit the outgrowth of autologous EB virus 
transformed lymphoblastoid cell lines (LCLs).  
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MATERIALS AND METHODS 
 
Preparation of Peripheral Blood Lymphocytes 
(PBLs) 
Blood samples (30-50 mls) were collected from 
healthy EBV seropositive donors [4 males (A, B, D, 
F), aged 30-40 years] into heparinzed RPMI 1640 
medium. Then peripheral blood lymphocytes (PBLs) 
were separated using lymphocyte separation medium 
(ICN, FLOW ICN Biomedical, Thane Oxfordshire 
UK) and tested on the same day against autologous 
human lymphoblastoid cell lines (LCLs). 
 
Cell Culture and Establishment of EBV-
Transformed LCLs 
Human EBV-transformed LCL was established 
from peripheral blood lymphocytes as previously 
described.10 Briefly, frozen virus stocks prepared from 
the B95-8 cell line and having a titre of 105 
lymphocyte transforming units per ml were thawed 
quickly and diluted 1 in 5 in tissue culture medium 
and 0.5 ml was added to 2 x 106 human lymphocytes. 
Cells were incubated in a CO2 incubator at 37º C for 1 
hour with regular shaking.  
Cells were then washed and resuspended at the 
required cell concentration in 10% FCS RPMI 1640 
medium containing 100 IU/ml penicillin, 100 µg/ml 
streptomycin and 1% phytohaemaglutinin (PHA) (1% 
solution of a stock). The cells were plated out in 2ml 
wells and incubated in 5% CO2 in a humidified 
incubator at 37ºC.  
After 2-3 days, the cells were stimulated with 
PHA, clumped together and blast cells appeared. EBV 
transformed clumps were grown and cell numbers 
increased. The cells were sub-cultured into fresh wells 
for 2-3 weeks and then into 25 cm² plastic tissue 
culture flasks. After establishment, LCLs were fed 
twice a week by doubling the volume or replacing 
half the culture with fresh medium.  
 
Regression Assay  
PBLs from seropositive human donors (A, B, D, 
F) and one seronegative human donor (C) were tested 
for their ability to inhibit the outgrowth of their 
autologous LCL.  
LCLs from the relevant autologous donor were 
plated out in round bottomed wells in 96 well plates 
(Corning, UK) as target cells at serial dilution ranging 
from 2.5 x 104 to 1.7 x 102 cells per 0.2 ml well. 12 
wells were plated out per dilution. PBLs were 
prepared from the autologous sample and added to 6 
wells of each dilution (48 wells) at 2.5 x 104 cells / 
well (Table 1).  
The cultures were incubated at 37oC in 5% CO2 
and observed twice a week for up to 4 weeks to 
determine the incidence of successful target cell 
outgrowth. The plates were fed weekly. Wells were 
observed using an inverted microscope and scored 
positive when characteristic progressively growing 
foci of the target LCLs were present. The effect of the 
PBLs on the outgrowth of the LCLs was calculated by 
the method of Reed-Munch.13  
The data for this experiment was collected from 
the minimum number of autologous LCL cells 
required for a 50% incidence of successful outgrowth 
in the presence of PBLs in a multiwell dish with serial 
dilutions of target cells and after an appropriate 
incubation period when the wells showed successful 
outgrowth, the dilution was then estimated by 
determining the proportionate distance between the 
highest and lowest dilutions that would correspond to 
50% of successful outgrowth.  
 
RESULTS 
 
Table 1 shows the results of a regression assay. 
Inspection of the data in donors (A, B, D, F) revealed 
that a 6x 103 dilution of target cells resulted a 
successful outgrowth in more than 50% whereas a 3x 
103 dilution of target cells resulted in a successful 
outgrowth in fewer than 50%. Thus, the dilution that 
would yield a 50% incidence of successful outgrowth 
in all donors exactly lied between 6x 103 and 3x 103.  
Figure 1 shows an ability of PBLs prepared from 
human seropositive donors (A, B, D, F), to inhibit the 
outgrowth of autologous LCLs. 
The minimum number of autologous LCL cells 
required for a 50% incidence of successful outgrowth 
in the presence of PBLs for A donor being 4 x 103, B 
donor 4.5  x 103, D donor 3.8 x 103, and F donor 4.1 x 
103. No inhibition of the outgrowth of the autologous 
LCL was seen after 4 weeks by the addition of PBLs 
with EBV seronagative (C donor). 
 
DISCUSSION 
 
The capacity of EBV to infect and transform B 
lymphocytes in vitro has provided an accessible 
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Table 1. Incidence of successful outgrowth after 4 weeks of EBV-transformed target cells (LCLs). 
 
Seronagative 
human 
donor C 
Seropositive 
human 
donor A 
Seropositive 
human 
donor B 
Seropositive 
human 
donor D 
Seropositive 
human 
donor F 
Number of target 
cells seeded per U 
well 
LCL 
alone 
LCL + 
2.5 x104 
PBLs 
LCL 
alone 
LCL + 
2.5 x 104 
PBLs 
LCL 
alone 
LCL + 
2.5 x 104 
PBLs 
LCL 
alone 
LCL + 
2.5 x 104 
PBLs 
LCL 
alone 
LCL + 
2.5 x 104 
PBLs 
2.5 × 104 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 
1.25 × 104 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 
6 × 103 6/6 6/6 6/6 4/6 6/6 5/6 6/6 3/6 6/6 4/6 
3 × 103 6/6 6/6 6/6 3/6 6/6 0/6 6/6 1/6 6/6 2/6 
1.5 × 103 6/6 6/6 6/6 0/6 6/6 0/6 6/6 0/6 6/6 0/6 
7 × 102 6/6 6/6 6/6 0/6 6/6 0/6 6/6 0/6 6/6 0/6 
3.5 × 102 6/6 6/6 6/6 0/6 6/6 0/6 6/6 0/6 6/6 0/6 
1.7 × 102 6/6 6/6 6/6 0/6 6/6 0/6 6/6 0/6 6/6 0/6 
Seeded in the presence and absence of autologous PBLs from four EBV seropositive donors (A, B, D, F) and one seronagative donor (C). 
6/6 indicates that LCLs were grown in all 6 wells;  0/6 all wells showed out growth of LCL at 4 weeks  
3/6 indicates that 3 of 6 wells were grown 
 
system with which to search for evidence of 
specific cellular immunity. This was first obtained 
with the demonstration that EBV-induced B cell 
transformation regresses in crowded cultures of 
infected lymphocytes from EBV immune, but not 
from EBV seronegative individuals.10,11 
The regression is mainly due to reactivation of 
MHC class I restricted memory cytotoxic T cell 
(CTL) responses11,12 though EBV-specific CD4 class 
II restricted cells have also been described.14,16 
Cytotoxic T Lymphocytes (CTLs) are important in the 
immune response to viral infection and play a crucial 
role in the host defence against viruses by recognizing 
viral antigens and eliminating virus- infected cells.14,15 
In the present work, cell mediated immune response 
was observed in four EBV-seropositive donors using 
a tissue culture growth inhibition assay after 4 weeks 
by the addition of peripheral blood lymphocytes 
whereas no inhibition of the outgrowth of the 
autologous LCL was seen with lymphocytes from 
EBV-seronagative donor. 
The number of cells required for 50% regression 
of EBV-induced autologous LCLs in donors was 
similar to that in the other healthy subjects. This 
indicates the persistent nature of EBV infection, 
adequate memory cytotoxic T cell control of
 
 
Human seropositive donors 
Figure 1. Ability of PBLs from human seropositive donors (A, B, D, F), to inhibit it the outgrowth of autologous LCLs. 
  Donor A: 50% end point =4×103;      Donor B: 50% end point =4.5×103 
  Donor D: 50% end point =3.8×103;      Donor F: 50% end point =4.1×103 
  Donor C: 50% end point =  
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EBV-infected B lymphocytes. The regression 
phenomenon was never seen when the donors of 
PBLs were EBV-seronegative. Previous work has also 
shown that at least one in 103 to 104 circulating T 
lymphocytes are EBV-specific memory T-cells which 
are stable in seropositive donors.10,11 This life-long 
virus carrier state is presumably due to chronic, low-
grade replication of the virus at a permissive site in 
the oro-pharynx or naso-pharynx since EB virus can 
be detected in throat washings from the vast majority 
of seropositive human subjects.2,3 
More works should aim to study T-cell responses 
to the EBV latent proteins which are constitutively 
expressed in LCLs and the cell-mediated immune 
response to EBV envelope glycoprotein's and other 
lytic cycle products.  
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